R
Roland S. Annan
Researcher at GlaxoSmithKline
Publications - 71
Citations - 12332
Roland S. Annan is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Phosphorylation & Mass spectrometry. The author has an hindex of 40, co-authored 67 publications receiving 11568 citations. Previous affiliations of Roland S. Annan include Brigham and Women's Hospital & California Institute of Technology.
Papers
More filters
Journal ArticleDOI
Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior
Takeshi Sakurai,Akira Amemiya,Makoto Ishii,Ichiyo Matsuzaki,Richard M. Chemelli,Hirokazu Tanaka,S. Clay Williams,James A. Richardson,Gerald P. Kozlowski,Shelagh Wilson,Jonathan R.S. Arch,Robin E. Buckingham,Andrea C. Haynes,Steven A. Carr,Roland S. Annan,Dean E. McNulty,Wu Schyong Liu,Jonathan A. Terrett,Nabil Elshourbagy,Derk J. Bergsma,Masashi Yanagisawa +20 more
TL;DR: Two novel neuropeptides are identified, both derived from the same precursor by proteolytic processing, that bind and activate two closely related (previously) orphan G protein-coupled receptors in the hypothalamus of rats.
Journal ArticleDOI
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin,Maureen R. Bleam,Arthur Groy,Katherine G. Moss,Elisabeth A. Minthorn,Swarupa G Kulkarni,Cynthia M. Rominger,Symon G. Erskine,Kelly E. Fisher,Jingsong Yang,Francesca Zappacosta,Roland S. Annan,David Sutton,Sylvie Laquerre +13 more
TL;DR: GSK1120212 combines high potency, selectivity, and long circulating half-life, offering promise for successfully targeting the narrow therapeutic window anticipated for clinical MEK inhibitors.
Journal ArticleDOI
Phosphorylation of Sic1p by G1 Cdk Required for Its Degradation and Entry into S Phase
Rati Verma,Roland S. Annan,Michael J. Huddleston,Steven A. Carr,G. Reynard,Raymond J. Deshaies +5 more
TL;DR: A molecular model of how phosphorylation and proteolysis cooperate to bring about the G1/S transition in budding yeast is suggested.
Journal ArticleDOI
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu,James G. Greger,Hong Shi,Yuan Liu,Joel Greshock,Roland S. Annan,Wendy S. Halsey,Ganesh M. Sathe,Anne-Marie Martin,Tona M. Gilmer +9 more
TL;DR: GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothelial growth factor receptor currently in phase II clinical trials, restores lapatinib and trastuzumab sensitivity in these resistant cells that exhibit increased AXL expression.
Journal ArticleDOI
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
Priya Chaturvedi,Wai K Eng,Yuan Zhu,Michael R. Mattern,Rubin Mishra,Mark R. Hurle,Xiaolong Zhang,Roland S. Annan,Quinn Lu,Leo F. Faucette,Gilbert F. Scott,Xiaotong Li,Steven A. Carr,Randall K. Johnson,James D. Winkler,Bin-Bing S. Zhou +15 more
TL;DR: Results suggest that Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway and might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with γ-radiation or with the topoisomerase-I inhibitor topotecan.